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Abstract
Background: Childhood asthma and obstructive sleep apnea (OSA), both disorders of airway inflammation, were associated
in recent observational studies. Although childhood OSA is effectively treated by adenotonsillectomy (AT), it remains
unclear whether AT also improves childhood asthma. We hypothesized that AT, the first line of therapy for childhood OSA,
would be associated with improved asthma outcomes and would reduce the usage of asthma therapies in children.
Methods and Findings: Using the 2003–2010 MarketScan database, we identified 13,506 children with asthma in the United
States who underwent AT. Asthma outcomes during 1 y preceding AT were compared to those during 1 y following AT. In
addition, 27,012 age-, sex-, and geographically matched children with asthma without AT were included to examine asthma
outcomes among children without known adenotonsillar tissue morbidity. Primary outcomes included the occurrence of a
diagnostic code for acute asthma exacerbation (AAE) or acute status asthmaticus (ASA). Secondary outcomes included
temporal changes in asthma medication prescriptions, the frequency of asthma-related emergency room visits (ARERs), and
asthma-related hospitalizations (ARHs). Comparing the year following AT to the year prior, AT was associated with
significant reductions in AAE (30.2%; 95% CI: 25.6%–34.3%; p,0.0001), ASA (37.9%; 95% CI: 29.2%–45.6%; p,0.0001), ARERs
(25.6%; 95% CI: 16.9%–33.3%; p,0.0001), and ARHs (35.8%; 95% CI: 19.6%–48.7%; p= 0.02). Moreover, AT was associated
with significant reductions in most asthma prescription refills, including bronchodilators (16.7%; 95% CI: 16.1%–17.3%; p,
0.001), inhaled corticosteroids (21.5%; 95% CI: 20.7%–22.3%; p,0.001), leukotriene receptor antagonists (13.4%; 95% CI:
12.9%–14.0%; p,0.001), and systemic corticosteroids (23.7%; 95% CI: 20.9%–26.5%; p,0.001). In contrast, there were no
significant reductions in these outcomes in children with asthma who did not undergo AT over an overlapping follow-up
period. Limitations of the MarketScan database include lack of information on race and obesity status. Also, the MarketScan
database does not include information on children with public health insurance (i.e., Medicaid) or uninsured children.
Conclusions: In a very large sample of privately insured children, AT was associated with significant improvements in several
asthma outcomes. Contingent on validation through prospectively designed clinical trials, this study supports the premise
that detection and treatment of adenotonsillar tissue morbidity may serve as an important strategy for improving asthma
control.
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Introduction
Asthma is a highly prevalent condition that currently ranks as
the third most prevalent chronic disease in children, and is
estimated to affect 7.1 million US children under the age of 18 y
[1]. Furthermore, asthma is the third leading cause of hospital-
ization among US children under the age of 15 y [2], and in 2010
alone, there were approximately 640,000 pediatric emergency
room visits related to asthma [3]. The consequences of asthma are
further illustrated by the inordinately elevated annual direct health
care costs of pediatric asthma, which amount to approximately
US$50.1 billion in the US, with an additional indirect cost of
US$5.9 billion attributable to lost productivity related to missed
school days and, secondarily, missed work days for parents [4].
The mainstay of asthma control is adherent daily administration
of anti-inflammatory therapies, including inhaled corticosteroids,
inhaled corticosteroids combined with long-acting b2 agonists, and
leukotriene receptor antagonists. Other important aspects aiming
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to optimize asthma control include avoidance of asthma triggers
such as seasonal allergens and environmental pollution, particu-
larly tobacco smoke exposure. However, recent studies have found
asthma to be associated with several frequently overlapping co-
morbidities including gastroesophageal reflux [5,6], obesity [7–9],
and sleep-disordered breathing [10–14], and have introduced
plausible therapeutic strategies aimed at improving asthma control
by minimizing or completely eradicating the burden of these
coexisting conditions.
Obstructive sleep apnea (OSA) is considered the most prevalent
and severe entity within the spectrum of sleep-disordered
breathing, and affects approximately 2%–3% of all children
[15–17]. Similar to asthma, the cardinal pathophysiological
feature associated with childhood OSA involves the presence of
increased airway inflammation, promoting the hypertrophy of
upper airway adenotonsillar tissues [18–21]. The latter, either
alone or in combination with other craniofacial and neuromus-
cular factors, promotes the presence of increased pharyngeal
resistance. Thus, when the expected loss of the physiological
dilator reflexes of the upper airway develops during sleep, these
hypertrophic tissues and their underlying inflammatory compo-
nents predispose the upper airway to episodically collapse, and
cause the gas exchange abnormalities and fragmented sleep that
characterize OSA [19]. Moreover, the repetitive upper airway
obstruction during sleep and accompanying intermittent hypox-
emia and hypercapnia, recurrent cortical microarousals, and
sympathetic nervous system activation trigger oxidative stress and
systemic inflammatory pathways that are currently believed to
mediate OSA-associated morbidities [22]. Consequently, surgical
adenotonsillectomy (AT) is considered the first line of therapy in
childhood OSA and has recently shown overall favorable
outcomes, including substantial improvements in the severity of
respiratory sleep disturbances [23–25] and in reducing markers of
OSA-associated systemic inflammation [26]. As anticipated,
secular trends have revealed an increased frequency of AT in
children over the past two decades related to a higher prevalence
of obstructive breathing [27], although rarely is a formal diagnosis
of OSA established through polysomnography by most otolaryn-
gologists before AT [28].
Recent evidence has suggested that the pathophysiological
complications of asthma and OSA may overlap in children,
supporting the ‘‘united airway hypothesis’’ [29]. Numerous
survey-based studies have reported a strong severity-dependent
association between OSA and symptoms of asthma [10,30–39].
Moreover, in a single-center cohort study of children with
asthma, AT for those children who had polysomnographic
evidence of OSA reduced the frequency of asthma exacerbations
and of bronchodilator usage, and led to substantial improvements
in pulmonary function [12]. However, to our knowledge, a
systematic examination of the association of AT with asthma
outcomes in a large sample of children has never been performed.
To that end, we employed the MarketScan database, which
contains a large longitudinal cohort of children with private
health insurance, and extracted all those children with asthma
diagnostic codes and asthma-specific pharmacy reimbursements.
We examined the frequency of specific asthma outcomes before
and after AT. Further, we compared these outcomes with
matched children with asthma who did not undergo AT in order
to evaluate the natural history of asthma over time [40]. We
hypothesized that removal of the adenoids and tonsils, thereby
improving sleep-disordered breathing and plausibly eradicating
OSA, would be associated with substantial improvements in
asthma control.
Methods
Ethics Statement
This study was approved by the University of Chicago’s
Institutional Review Board (BSD/UCH IRB approval no. 10-
567-E).
Data Source
All data were obtained using the MarketScan database, which
provides access to a large database of over 180 million patients
with private health insurance since 1995, including a large cohort
of children (.25 million children). The MarketScan database
collects payment information, capturing reimbursements from the
health insurance plans and payments accrued by patients. It
provides access to integrated patient-level data on expenses using
billable codes in both the inpatient and outpatient settings, and
also includes access to patient-level pharmacy expenses. Children
were identified for a study period between January 1, 2003, and
December 31, 2010.
Participant Selection
Children aged 3 to 17 y with asthma were identified from the
MarketScan database using asthma-specific International Classi-
fication of Diseases, Ninth Revision–Clinical Modification (ICD-9-
CM) codes of asthma (493.XX). From this cohort, all children with
asthma who had undergone AT were identified using current
procedural terminology (CPT) codes specific for AT (CPT for AT
for children aged ,12 y is 42820, and for AT for children aged .
12 y is 42821). Our cases (AT+) served as their own controls for
the 1 y preceding AT. In addition, we studied a second group of
matched children with asthma who did not undergo AT (AT2).
These children were chosen if they met the above criteria for
asthma, but did not have a history of any CPT codes for AT,
adenoidectomy, or tonsillectomy. The purpose of adding this
group was to include a cohort of children with asthma from the
database in order to characterize the natural history of asthma
when there is no confounding influence of complications related to
adenotonsillar hypertrophy. This is of particular relevance since
asthma severity improves with age, and recent evidence advocates
the inclusion of a control group of children with asthma in studies
examining the efficacy of an intervention in asthma [40]. AT2
children were matched using a 2:1 ratio to AT+ children, and were
selected using a greedy selection algorithm according to age, sex,
home location (urban or rural), and geographical state of residence
based on a macro employed by SAS software, version 9.3. The
greedy algorithm selects matched controls based on selecting the
next ideal match in the fewest steps, without spanning the entire
database to choose the best match.
Because of the technical and ethical constraints of the Market-
Scan database, the dataset does not contain information on
ethnicity or obesity status. In both AT+ and AT2 children, the
presence of ICD-9-CM codes corresponding to any confounding
disease that could influence the respiratory tract and/or affect the
efficacy of AT in the treatment of sleep-disordered breathing led to
exclusion (Figure 1).
After implementation of the stringent selection criteria to form
our study population, the temporal nature of study outcomes was
entirely based on the timing of AT. For children with asthma who
had undergone AT (AT+), the frequency of outcomes was
examined during 1 y prior to the AT date and compared to
during 1 y following the AT date. In children with asthma without
a history of AT (AT2), the frequency of outcomes was examined
over a similar 2-y period, such that AT2 children had the same
age, sex, home location, and geographical state as AT+ children at
Adenotonsillectomy and Asthma in Children
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the time of AT, with the frequency of outcomes being defined as
during the 1 y before and the 1 y after the arbitrary date of
January 1. We examined a 2-y time period (1 y pre-AT and 1 y
post-AT for AT+ children, and first and second year of follow-up
for AT2 children) in order to capture the frequency of asthma
events over all four seasons. Of note, longer follow-up periods
incurred a greater probability that children would drop out
because of incomplete follow-up time or a higher likelihood that
children would change health insurance providers. A clear
limitation of the MarketScan database is that in the event that a
child changes health insurance coverage, a new identification code
is created, such that under these circumstances one child might be
included as two separate children instead of one. Therefore, AT+
children without 1 y of pre-AT and 1 y of post-AT data and AT2
children without 2 y of data under the same identification code
were not included. Finally, only children from the continental
United States and Alaska were included (i.e., children from
Hawaii, Puerto Rico, Guam, and the US Virgin Islands were
excluded).
Study Outcomes
The primary outcomes for the present study were the frequency
of ICD-9-CM codes (Table S1) for acute asthma exacerbation
(AAE) and acute status asthmaticus (ASA). Secondary outcomes
included the frequency of additional surrogates of asthma status
such as ICD-9-CM codes (Table S1) for acute bronchospasm and
wheezing, and CPT codes for spirometry, intubation, and
initiation of ‘‘continuous inhalation for the first hour,’’ which
would suggest an asthma exacerbation requiring continuous
bronchodilator therapy, as is commonly performed in the
emergency room setting.
In addition, since the MarketScan database provided outpatient
pharmacy reimbursement claims in 10,663 AT+ children (79%)
and 21,023 AT2 children (78%), an additional secondary
outcome was the frequency of asthma-specific outpatient medica-
tion prescription reimbursement (Table S2) during the same
periods. For systemic corticosteroids we searched the database for
generic and brand names of oral forms (tablet, syrup, elixir) of
prednisone and prednisolone.
Finally, we examined all asthma-related emergency room
visits (ARERs) and asthma-related hospitalizations (ARHs) by
screening emergency room visits and hospitalizations in which
the primary or secondary diagnostic code was billed for AAE or
ASA (Table S1) or acute bronchospasm or wheezing (CPT
codes).
Statistical Analysis
Demographic data between AT+ and AT2 children were
compared using one-way ANOVA for age and chi-square for
categorical outcomes. In the setting of multiple variables, such as
in home location, a Wilcoxon matched-pairs signed rank test was
used to compare AT+ to AT2 children.
Figure 1. Selection of children from the MarketScan database following exclusion of specific comorbidities. Both AT+ and AT2
children had to have data for 1 y prior to and 1 y after the index date (AT surgery or January 1) to be included. AT+ children were selected if they had
an identified diagnostic code for asthma and AT. Matched AT2 children were selected according to a 2:1 ratio to AT+ children using a greedy
selection algorithm. AT2 children had a code for asthma without an identified diagnostic code for AT, adenoidectomy, or tonsillectomy. SMA, spinal
muscular atrophy.
doi:10.1371/journal.pmed.1001753.g001
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We used Fisher’s exact test or chi-square with Yates’ correction
if the sample size was particularly large to compare the frequency
of outcomes between AT+ and AT2 children. Confidence
intervals of proportions of a population were determined using a
Wilson score interval.
Results
For the study period January 1, 2003, to December 31, 2010,
we identified 1,733,278 million children with asthma of a total of
23,340,142 million enrollees (ages 3–17 y) available in the
database (prevalence of 7.4%) (Figure 1). Following exclusion of
co-morbidities, we identified 51,794 children who had both an
ICD-9-CM code for asthma and had undergone AT. Inclusion of
children that had 1 y of data both pre- and post-AT reduced the
number of AT+ children to 13,506 (Figure 1). Children excluded
from the AT+ group because of insufficient follow-up data or
because they did not reside in the continental United States did
not markedly differ from children included in the AT+ group in
distribution of age, gender, home location, and availability of
pharmacy reimbursement claims. There were, however, observed
differences in diagnostic codes provided for AT (Table S3).
Following exclusion of co-morbidities, 932,606 candidate AT2
children that fulfilled the 2-y follow-up requirement were
identified from the database. Using a greedy selection algorithm
with a target ratio of two AT2 children for each AT+ child
provided 27,012 AT2 children who were successfully matched to
AT+ children for age (Figure S1), sex, home location (Table 1),
and geographical state of residence. Only the diagnostic codes of
adenotonsillar hypertrophy, adenotonsillitis, sleep apnea, snoring,
and sleep disturbance were significantly higher in the AT+ group
(Table 1).
The frequency of episodes of AAE and ASA declined
significantly in AT+ children following AT, while such frequency
only slightly decreased in AT2 children between the first year and
the second year of follow-up. Indeed, the frequency of AAE was
reduced from 2,243 pre-AT to 1,566 post-AT in the AT+ children,
as compared to 3,403 in the first year and 3,336 in the second year
in AT2 children (30% versus 2% relative risk reduction; p,
0.0001; Table 2). Similarly, the frequency of ASA decreased in
AT+ children from 562 pre-AT to 349 post-AT, as compared to
837 in the first year and 778 in the second year in AT2 children
(38% versus 7% relative risk reduction; p,0.0001) (Table 2).
When comparing each primary outcome individually, significant
reductions associated with AT occurred in nearly all outcomes
(Table S1). When the number of episodes was normalized per
1,000 children, the frequency of AAE and ASA was higher in
children in the AT+ group prior to AT than in the AT2 group in
Table 1. Demographic summary of case (adenotonsillectomy) and control populations.
Characteristic AT+ Group AT2 Group (2:1 Match) p-Value
Number of children 13,506 27,012
Diagnostic code
474.16 (hypertrophy of tonsils and adenoids) 5,942 (44%) 537 (2%) ,0.0001
474.06 (chronic tonsillitis and adenoiditis) 3,062 (23%) 137 (0.5%) ,0.0001
474.16, 474.06 (hypertrophy of tonsils and adenoids and
chronic tonsillitis and adenoiditis)
2,344 (17%) 265 (1%) ,0.0001
327.20, 327.23, 327.24, 327.26, 327.29, 780.51, 780.53, 780.57,
786.03, 780.50, 780.56, 780.59 (sleep apnea, snoring,
and/or sleep disturbance)
3,603 (27%) 1,099 (1%) ,0.0001
Age in years, mean ± standard deviation 7.7063.65 7.6863.66 0.49
Gender
Male 7,440 (55%) 14,880 (55%) 1.00
Female 6,066 (45%) 12,132 (45%)
With available pharmacy reimbursement claims 10,663 (79%) 21,023 (78%) 1.00
Home location 0.98
Metropolitan counties
Counties in metro areas of 1 million population or more 6,116 (45.2%) 12,249 (45.3%)
Counties in metro areas of 250,000–1,000,000 population 2,746 (20.3%) 6,088 (22.5%)
Counties in metro areas of fewer than 250,000 population 1,896 (14.0%) 3,597 (13.3%)
Nonmetropolitan counties
Urban population of 20,000 or more, adjacent to a metro area 756 (5.6%) 1,463 (5.4%)
Urban population of 20,000 or more, not adjacent to a
metro area
278 (2.1%) 607 (2.2%)
Urban population of 2,500–19,999, adjacent to a metro area 1,024 (7.6%) 1,751 (6.5%)
Urban population of 2,500–19,999, not adjacent to a metro area 442 (3.3%) 846 (3.1%)
Completely rural or urban population of less than 2,500,
adjacent to a metro area
124 (0.9%) 222 (0.8%)
Completely rural or urban population less than 2,500,
not adjacent to a metro area
124 (0.9%) 189 (0.7%)
Values are number (percent) unless otherwise stated. p-Value is for the difference between the two groups.
doi:10.1371/journal.pmed.1001753.t001
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the first year of follow-up (Figure 2A and 2B). However, in the 1 y
following AT, the frequency of AAE and ASA in AT+ children
reached levels similar to those of AT2 children in the second year
of follow-up. The overall reductions in AAE and ASA (i.e., post-
AT 1 y minus pre-AT 1 y) among AT+ children were present
across the age spectrum (Figure 2C and 2D).
Additionally, there were statistically significant reductions in
health care provider coding for acute bronchospasm, wheezing,
spirometry usage, and continuous inhalation therapy for the first
hour in AT+ children following AT relative to corresponding
matched AT2 children in the analogous second year of follow-
up (Table 3; Figure 3). The frequency of coding for endotra-
Figure 2. Annual incidence of primary asthma outcomes (acute asthma exacerbation and acute status asthmaticus). Annual incidence
of AAE (A) and ASA (B) expressed per 1,000 children. Red bars represent 1 y prior to AT in AT+ children or the first year of follow-up in AT2 children;
green bars represent 1 y after AT or the second year of follow-up. The difference in annual incidence of AAE (C) and ASA (D) is calculated by
subtracting the incidence during 1 y pre-AT (or first year of follow-up in AT2 children) from the incidence during 1 y post-AT (or second year of
follow-up in AT2 children). Black circles represent the AT+ group, and white squares represent the AT2 group. All error bars represent the 95th
percentile confidence intervals for a sample proportion.
doi:10.1371/journal.pmed.1001753.g002
Table 2. Annual incidence of acute asthma exacerbation and acute status asthmaticus: comparing adenotonsillectomy to no
adenotonsillectomy.
Item AAE ASA
AT+ Group AT2 Group AT+ Group AT2 Group
1 y pre-AT/first year 2,243 3,403 562 837
1 y post-AT/second year 1,566 3,336 349 778
Percent reduction 30.0% (25.6% to 34.3%) 2.0% (22.5% to 6.3%) 37.9% (29.2% to 45.6%) 6.8% (22.6% to 15.4%)
p-Value p,0.0001 p,0.0001
Data are number or percent (95% CI). p-Value is for the difference between the two groups.
doi:10.1371/journal.pmed.1001753.t002
Adenotonsillectomy and Asthma in Children
PLOS Medicine | www.plosmedicine.org 5 November 2014 | Volume 11 | Issue 11 | e1001753
cheal intubation, however, was not different between the two
groups.
The information available on pharmacy reimbursements in the
MarketScan database provides data regarding the number of
prescription refills during the study period as well as the number of
children filling a specific prescription. We chose to investigate both
measures since in some children, particularly those with poorly
controlled asthma, numerous prescriptions may have been refilled
during the 2-y period. Regarding prescription refills, compared to
AT2 children, AT+ children having undergone AT had
significant decreases in most classes of asthma prescriptions in
the 1 y following AT. There was a 16.7% reduction in prescription
refills for bronchodilators, a 21.5% reduction for inhaled
corticosteroids, and a 13.4% reduction for leukotriene receptor
antagonists (Table 4). However, there were no reductions in
prescription refills of combination inhaled corticosteroids/long-
acting b2 agonists, typically reserved for children with severe
asthma, while in AT2 children there was a 20.1% increase in the
number of such prescriptions (Table 4).
Upon examination of the number of children who filled various
asthma prescriptions after normalizing per 1,000 children
(Figure 4A), it is apparent that prior to AT, more AT+ children
required prescriptions for bronchodilators, inhaled corticosteroids,
and leukotriene receptor antagonists, and the number of AT+
children requiring these therapies declined to levels similar to
those of AT2 children following AT.
The number of prescription refills of systemic corticosteroids,
which could indicate an asthma exacerbation, was markedly
reduced in AT+ children following AT compared to the analogous
second year of follow-up in AT2 children (23.7% versus 7.3%
reduction; p=0.003) (Table 4). When examining the number of
children needing systemic corticosteroids after normalizing the
data per 1,000 children (Figure 4B), a larger proportion of AT+
children than AT2 children needed systemic corticosteroids
during the year prior to AT/first year of follow-up, but after
AT, systemic corticosteroid use by AT+ children reached a level
similar to that of AT2 children in the second year of follow-up.
Finally, assessment of the difference in the number of children
filling a prescription for either bronchodilator or systemic
corticosteroid therapies (Figure 4C and 4D, respectively) from
the year pre-AT to the year post-AT revealed that the reduction of
bronchodilator therapy post-AT was consistently present at all
ages in AT+ children, while the reduction in systemic corticoste-
roids in AT+ children appeared to occur mostly in children ,10 y
of age.
The numbers of ARERs and ARHs were also significantly
reduced following AT in AT+ children compared to AT2
children in the second year of follow-up (25.6% versus 0.0%
reduction; p,0.0001; and 35.8% versus 12.2% reduction;
p=0.0025) (Table 5). Following normalization of the number of
children per 1,000 children (Figure 5), the frequency of severe
asthma as related to the frequency of ARERs and ARHs was
higher in AT+ children pre-AT and improved to levels compa-
rable to those of AT2 children following AT.
Discussion
In this large sample of privately insured children with asthma, we
examined longitudinal data and found that in children with asthma
but without other significant comorbidities, AT was associated with
significant decreases in asthma exacerbations as well as reductions in
asthma-specific medication refills. The rationale of the current study
was to examine whether the proposed overlap of two commonly
inflammatory conditions in children, namely, asthma andOSA, leads
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to interdependent effects on the severity of the disease. To
purposefully address our objective, we assumed that the primary
indication for AT among most children in this cohort is for symptoms
of OSA, and substantial evidence supports this assumption [27].
Accordingly, current findings support the possibility that the presence
of OSA aggravates underlying asthma in children, and that treatment
of OSA (via AT) might ameliorate the severity of asthma and reduce
the need for more intensive use of anti-asthmatic medications.
However, prospective trials are necessary to establish a causal
relationship.
Figure 3. Annual incidence of secondary asthma outcomes expressed per 1,000 children. Red bars represent 1 y pre-AT in AT+ children or
first year of follow-up in AT2 children; green bars represent 1 y post-AT or second year of follow-up. All error bars represent the 95th percentile
confidence intervals for a sample proportion. (A) Annual incidence of billing codes for acute bronchospasm, wheezing, and intubation. (B) Annual
incidence of billing codes for spirometry and continuous inhalation for first hour.
doi:10.1371/journal.pmed.1001753.g003
Adenotonsillectomy and Asthma in Children
PLOS Medicine | www.plosmedicine.org 7 November 2014 | Volume 11 | Issue 11 | e1001753
Before we discuss the potential implications of the current
findings, some methodological issues deserve comment. We
believe that the use of AT CPT codes provides a reasonably
reliable surrogate indicator for the presence of OSA, particularly
considering that during the period covered in the study, the vast
majority of ATs were performed as treatment for OSA [27]. We
deliberately used CPT codes for AT instead of ICD-9-CM codes
for OSA. A priori evaluation of our AT+ and AT2 children
revealed that only 842 (6.2%) of the AT+ children and 159 (0.6%)
of the AT2 children had undergone some form of evaluation for
sleep-disordered breathing as determined by searching for specific
sleep diagnostic testing CPT codes (Table S4). This observation is
consistent with previous studies indicating that the vast majority of
children undergoing AT are unlikely to undergo formal diagnostic
polysomnography testing for OSA [41,42]. In order to capture the
large population of children with OSA treated with AT in whom
diagnostic testing was not conducted, confirmation of OSA by
concurrent utilization of the sleep diagnostic CPT codes was
precluded. Given the secular trends whereby OSA is the major
indication for AT in up to 80% of children [27], we surmise that
most children in our study underwent AT for symptoms of OSA.
Despite the paucity of diagnostic polysomnography in the AT+
group, 27% of children did have an insurance claim for a
diagnostic code of sleep apnea, snoring, or sleep disturbance, and
44% of children had an insurance claim for adenotonsillar
hypertrophy during the 1-y period prior to surgery. Only 23%
of children had an isolated insurance claim of chronic tonsillitis
and adenoiditis (Table 1).
In addition, the diagnosis of asthma is particularly problematic
in younger children, given their limited ability to participate in
diagnostic pulmonary function testing including methacholine or
exercise bronchial provocation testing. Moreover, virally induced
wheezing during early childhood may often be incorrectly labeled
as asthma. To partially overcome this limitation, we separately
analyzed children under 6 y of age and older children (Table 6).
The associations between AT and improvements in asthma
outcomes remained essentially unchanged from analyses in which
all children were included independent of age.
Notwithstanding the challenges of identifying correctly the
diagnosis of OSA and asthma using the MarketScan database, it is
well established that the similarities between asthma and OSA in
children are quite extensive. Indeed, both are considered
inflammatory disorders of the airways as well as low-grade
systemic inflammatory diseases [20,43,44]. Asthma and OSA also
share risk factors such as allergic rhinitis, obesity, exposure to
tobacco smoke, frequent respiratory infections, and African-
American race [45,46]. In addition, rhinitis, commonly associated
with OSA, is also considered a precursor to asthma [47]. The
association of allergic rhinitis with both OSA and asthma suggests
biological plausibility for the idea that OSA is related to asthma,
and suggests that in the treatment of OSA, AT potentially
improves asthma status by reducing the burden of allergic disease
and inflammatory disease of the upper airway. Moreover, the
seasonal variation of pediatric OSA is remarkably similar to the
seasonal variation of asthma status [48–50]. Thus, although this
study supports an association and by no means confirms causality,
there is a rationale to support a biologically plausible link between
asthma and adenotonsillar morbidity, namely OSA.
Furthermore, a relatively large number of questionnaire-based
studies assessing symptoms of asthma or the presence of snoring
have thus far supported the presence of an association between
OSA and recurrent wheezing and/or asthma across many regions
and states [10,30–39]. Notwithstanding the limitations of such
questionnaire-based surveys, there appears to be a severity-
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dependent effect, whereby more severe OSA is associated with
poorer asthma control [11]. Although randomized controlled
studies are needed to prove cause and effect between OSA and
asthma, the present findings provide a compelling argument in
favor of such studies, considering the putative improvements that
emerged in asthma-related health care utilization following AT.
The current results are supportive of the findings in three
previous studies [12,51,52]. Saito and colleagues [51] reported
that in 25 patients with asthma, AT improved asthma symptoms in
88%, with 60% of children able to eliminate all of their asthma
therapies, and 28% able to eliminate some of their therapies [51].
In a retrospective study of 93 children with asthma, AT was
associated with significant reductions of asthma therapies,
including corticosteroids, and with improvements in asthma
[52]. Finally, Kheirandish-Gozal and colleagues [12] demonstrat-
ed in a prospective study that AT for polysomnographically
demonstrated OSA was associated with reduced symptoms and
rescue inhaler therapy usage in 35 children with poorly controlled
asthma, and further reported significant improvements in pulmo-
nary function following AT. However, these three studies included
small sample sizes and short follow-up periods that clearly limit
their generalizability [12,51,52]. None of these studies compared
children with asthma who underwent AT to a group of children
with asthma who did not undergo AT, an important issue since
improvements in asthma status seen following AT in these three
studies could also be related to seasonal variation, or related to a
spontaneous improvement in asthma control over time through
growing older [40]. In order to address these limitations, our study
included a very large sample of privately insured children with
asthma who underwent AT compared to children with asthma
who did not undergo AT. Moreover, we took advantage of the
MarketScan database, which includes features of health care
resource utilization over time for our longitudinal comparisons.
Although the database provides information on a large sample of
Figure 4. Annual number of children using asthma-specific prescription therapies. (A) Annual number of children using various asthma
therapies expressed per 1,000 children. Solid red bars: AT+ group 1 y pre-AT; solid green bars: AT+ group 1 y post-AT. Red striped bars: AT2 group
first year of follow-up; green striped bars: AT2 group second year of follow-up. (B) Annual number of children using systemic corticosteroids
expressed per 1,000 children. (C) The difference in the number of children filling a prescription for a bronchodilator, subtracting the number during
1 y pre-AT (or first year of follow-up in AT2 group) from the number during 1 y post-AT (or second year of follow-up). Black circles represent AT+
group means, and white squares represent AT2 group means. (D) The difference in the number of children filling a prescription for a systemic
corticosteroid therapy, subtracting the number during 1 y pre-AT (or first year of follow-up in AT2 group) from the number during 1 y post-AT (or
second year of follow-up). Black circles represent AT+ group, and white squares represent AT2 group. All error bars represent the 95th percentile
confidence intervals for a sample proportion. BD, bronchodilator; ICS, inhaled corticosteroid; ICS/LABA, inhaled corticosteroid with long-acting b2
agonist; LTRA, leukotriene receptor antagonist.
doi:10.1371/journal.pmed.1001753.g004
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privately insured children, it does not include any data on the large
group of uninsured children or those receiving health care services
through public health insurance such as Medicaid. On the other
hand, our data exclude the confounding effect of lack of access to
health care, as all children included in our cohort were privately
insured.
Our study has several additional limitations that are primarily
inherent to the analysis of large administrative databases. Some of
our outcomes were based entirely on physician billing practices.
While there is a possibility of coding error or reporting bias, there
is no reason to assume that such errors or biases differ among AT+
and AT2 children. Furthermore, the inclusion of data on
prescription refills as an additional outcome measure in this study
provides additional objective outcomes that are not dependent on
physician billing practices. As mentioned earlier, the MarketScan
database does not provide information regarding the ethnicity of
children. The racial disparities regarding health care utilization
are very relevant to asthma control [53,54]. In addition, data were
not available for obesity status, and therefore we were unable to
control for body mass index, another important risk factor in
asthma prevalence and severity [7,55]. We acknowledge that race
and obesity are important confounding variables for asthma status,
and the unavailability of data on both race and obesity status
represents an important limitation, particularly with regard to our
selection of matching control children with asthma who did not
undergo AT. In spite of this limitation, we believe that matching a
child’s home location and geographical state to the level of county
of residence—a surrogate of a child’s socioeconomic status—can
serve to minimize any potential discrepancies in race and obesity
status between the two groups (Table 1) [56]. Although our
dataset included children who received services up to 2010, we do
not anticipate any change in the association between AT and
asthma since 2010.
Notwithstanding the study’s limitations, using a large sample
size of carefully selected children with asthma who underwent AT,
we demonstrated that AT was associated with reduced asthma
severity and improved control. Moreover, asthma-related out-
comes in children after AT were comparable to those in children
with asthma who did not undergo AT. While recent evidence
reveals that the most common reason for AT in the United States
Figure 5. Annual frequency of asthma-related emergency room visits and asthma-related hospitalizations expressed per 1,000
children. (A) ARERs and (B) ARHs. Red bars represent 1 y prior to AT in the AT+ group and the first year of follow-up in the AT2 group; green bars
represent 1 y post-AT in the AT+ group and the second year of follow-up in the AT2 group. All error bars represent the 95th percentile confidence
intervals for a sample proportion.
doi:10.1371/journal.pmed.1001753.g005
Table 5. Annual frequency of asthma-related emergency room visits and asthma-related hospitalizations: comparing
adenotonsillectomy to no adenotonsillectomy.
Item ARERs ARHs
AT+ Group AT2 Group AT+ Group AT2 Group
1 y pre-AT/first year 712 977 193 375
1 y post-AT/second year 530 1,056 124 329
Percent reduction 25.6% (16.9% to 33.3%) 0.0% 35.8% (19.6% to 48.7%) 12.3% (21.6% to 24.3%)
p-Value p,0.0001 p=0.0247
Data are number or percent (95% CI). p-Value is for the difference between the two groups.
doi:10.1371/journal.pmed.1001753.t005
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is OSA [27], it is important to acknowledge that this commonly
performed surgery is not without risk. Morbidities can range from
relatively minor hemorrhage and dehydration to more severe
complications including anoxic brain injury and death [57,58].
In summary, our findings provide additional evidence that AT is
associated with improved asthma control and suggest that OSA is
also associated with the severity of asthma in these children.
Further research is needed to better elucidate the pathways linking
OSA with asthma in order to establish biological plausibility and,
finally, to establish the criteria for identification of those children
with asthma most likely to develop OSA and to potentially benefit
from AT.
Supporting Information
Checklist S1 STROBE research checklist.
(DOCX)
Figure S1 Age distribution of the AT+ and AT2 groups.
Matched AT2 group children were chosen using a 2:1 ratio;
hence, at each age point there is an anticipated doubling in the
AT2 group (green bars) for the corresponding AT+ group (red
bars).
(TIF)
Table S1 ICD-9-CM and CPT codes used as study outcomes.
(DOCX)
Table S2 Asthma pharmacy classes used as study outcomes.
(DOCX)
Table S3 Demographic summary of children included in and
excluded from the AT+ group.
(DOCX)
Table S4 CPT codes used for sleep apnea diagnostic testing.
(DOCX)
Acknowledgments
The authors wish to thank Christopher Lyttle from the Center for Health
and Social Sciences at the University of Chicago for his support in
accessing the MarketScan database.
Author Contributions
Conceived and designed the experiments: RB DG BM. Performed the
experiments: RB BHC. Analyzed the data: RB BHC BM DG. Contributed
reagents/materials/analysis tools: RB BHC. Wrote the first draft of the
manuscript: RB. Wrote the paper: RB DG BM. ICMJE criteria for
authorship read and met: RB BHC DG BM. Agree with manuscript results
and conclusions: RB BHC DG BM. Collected data: RB BHC BM.
Participated in data interpretation and manuscript preparation: RB BHC
DG BM. Oversaw all analyses and take full responsibility for the work as a
whole, including the study design, access to data, and the decision to
submit and publish the manuscript: RB BM. Senior author: BM.
References
1. Centers for Disease Control and Prevention National Center for Health Statistics
(2011) National health interview raw data, 2011. Analysis by the American Lung
Association Research and Health Education Division using SPSS and SUDAAN
software. Atlanta (Georgia): Centers for Disease Control and Prevention.
2. Centers for Disease Control and Prevention National Center for Health
Statistics (2010) National Hospital Discharge Survey, 1995–2010. Analysis by
the American Lung Association Research and Health Education Division using
SPSS software. Atlanta (Georgia): Centers for Disease Control and Prevention.
3. Centers for Disease Control and Prevention National Center for Health
Statistics (2010) National Hospital Ambulatory Medical Care Survey, 2010.
Analysis by the American Lung Association Research and Health Education
Division using SPSS software. Atlanta (Georgia): Centers for Disease Control
and Prevention.
4. Barnett SB, Nurmagambetov TA (2011) Costs of asthma in the United States:
2002–2007. J Allergy Clin Immunol 127: 145–152.
5. Blake K, Teague WG (2013) Gastroesophageal reflux disease and childhood
asthma. Curr Opin Pulm Med 19: 24–29.
6. Harding SM, Richter JE (1997) The role of gastroesophageal reflux in chronic
cough and asthma. Chest 111: 1389–1402.
7. Figueroa-Munoz JI, Chinn S, Rona RJ (2001) Association between obesity and
asthma in 4–11 year old children in the UK. Thorax 56: 133–137.
8. Luder E, Melnik TA, DiMaio M (1998) Association of being overweight with
greater asthma symptoms in inner city black and Hispanic children. J Pediatr
132: 699–703.
9. Gennuso J, Epstein LH, Paluch RA, Cerny F (1998) The relationship between
asthma and obesity in urban minority children and adolescents. Arch Pediatr
Adolesc Med 152: 1197–1200.
10. Desager KN, Nelen V, Weyler JJ, De Backer WA (2005) Sleep disturbance
and daytime symptoms in wheezing school-aged children. J Sleep Res 14: 77–
82.
Table 6. Annual incidence of acute asthma exacerbation and acute status asthmaticus in children ,6 and children $6 y:
comparing adenotonsillectomy to no adenotonsillectomy.
Item AAE ASA
AT+ Group AT2 Group AT+ Group AT2 Group
Ages 6–17 y
1 y pre-AT/first year 1,286 2,111 343 490
1 y post-AT/second year 937 2,106 213 475
Percent reduction 27.1% (21.0% to 32.8%) 0.2% (25.7% to 5.9%) 37.9% (26.4% to 47.6%) 3.1% (29.9% to 14.5%)
p-Value p,0.0001 p,0.0001
Ages 3–5 y
1 y pre-AT/first year 957 1,292 219 347
1 y post-AT/second year 629 1,230 136 303
Percent reduction 34.3% (27.5% to 40.4%) 4.8% (22.7% to 11.8%) 38.2% (29.2% to 46.0%) 12.7% (21.8% to 25.1%)
p-Value p,0.0001 p= 0.0115
Data are number or percent (95% CI). p-Value is for the difference between the two groups.
doi:10.1371/journal.pmed.1001753.t006
Adenotonsillectomy and Asthma in Children
PLOS Medicine | www.plosmedicine.org 11 November 2014 | Volume 11 | Issue 11 | e1001753
11. Ramagopal M, Mehta A, Roberts DW, Wolf JS, Taylor RJ, et al. (2009) Asthma
as a predictor of obstructive sleep apnea in urban African-American children.
J Asthma 46: 895–899.
12. Kheirandish-Gozal L, Dayyat EA, Eid NS, Morton RL, Gozal D (2011)
Obstructive sleep apnea in poorly controlled asthmatic children: effect of
adenotonsillectomy. Pediatr Pulmonol 46: 913–918.
13. Ross KR, Storfer-Isser A, Hart MA, Kibler AM, Rueschman M, et al. (2012)
Sleep-disordered breathing is associated with asthma severity in children.
J Pediatr 160: 736–742.
14. Kheirandish-Gozal L, Gozal D (2012) Obesity, asthma, and sleep-disordered
breathing. J Pediatr 160: 713–714.
15. Ali NJ, Pitson DJ, Stradling JR (1993) Snoring, sleep disturbance, and behaviour
in 4–5 year olds. Arch Dis Child 68: 360–366.
16. Gislason T, Benediktsdottir B (1995) Snoring, apneic episodes, and nocturnal
hypoxemia among children 6 months to 6 years old. An epidemiologic study of
lower limit of prevalence. Chest 107: 963–966.
17. Montgomery-Downs HE, O’Brien LM, Holbrook CR, Gozal D (2004) Snoring
and sleep-disordered breathing in young children: subjective and objective
correlates. Sleep 27: 87–94.
18. Marcus CL, McColley SA, Carroll JL, Loughlin GM, Smith PL, et al. (1994)
Upper airway collapsibility in children with obstructive sleep apnea syndrome.
J Appl Physiol 77: 918–924.
19. Arens R, Marcus CL (2004) Pathophysiology of upper airway obstruction: a
developmental perspective. Sleep 27: 997–1019.
20. Goldbart AD, Krishna J, Li RC, Serpero LD, Gozal D (2006) Inflammatory
mediators in exhaled breath condensate of children with obstructive sleep apnea
syndrome. Chest 130: 143–148.
21. Kim J, Bhattacharjee R, Dayyat E, Snow AB, Kheirandish-Gozal L, et al. (2009)
Increased cellular proliferation and inflammatory cytokines in tonsils derived
from children with obstructive sleep apnea. Pediatr Res 66: 423–428.
22. Bhattacharjee R, Kim J, Kheirandish-Gozal L, Gozal D (2011) Obesity and
obstructive sleep apnea syndrome in children: a tale of inflammatory cascades.
Pediatr Pulmonol 46: 313–323.
23. Marcus CL, Brooks LJ, Draper KA, Gozal D, Halbower AC, et al. (2012)
Diagnosis and management of childhood obstructive sleep apnea syndrome.
Pediatrics 130: 576–584.
24. Bhattacharjee R, Kheirandish-Gozal L, Spruyt K, Mitchell RB, Promchiarak J,
et al. (2010) Adenotonsillectomy outcomes in treatment of obstructive sleep
apnea in children: a multicenter retrospective study. Am J Respir Crit Care
Med 182: 676–683.
25. Marcus CL, Moore RH, Rosen CL, Giordani B, Garetz SL, et al. (2013) A
randomized trial of adenotonsillectomy for childhood sleep apnea.
N Engl J Med 368: 2366–2376.
26. Gozal D, Serpero LD, Sans Capdevila O, Kheirandish-Gozal L (2008) Systemic
inflammation in non-obese children with obstructive sleep apnea. Sleep Med 9:
254–259.
27. Erickson BK, Larson DR, St Sauver JL, Meverden RA, Orvidas LJ (2009)
Changes in incidence and indications of tonsillectomy and adenotonsillectomy,
1970–2005. Otolaryngol Head Neck Surg 140: 894–901.
28. Mitchell RB, Pereira KD, Friedman NR (2006) Sleep-disordered breathing in
children: survey of current practice. Laryngoscope 116: 956–958.
29. Gozal D (2010) Pediatric OSA: a case for ‘‘united we stand’’ in the way of a
breath. Pediatr Pulmonol 45: 1151–1152.
30. Verhulst SL, Vekemans K, Ho E, Aerts L, Jacobs S, et al. (2007) Is wheezing
associated with decreased sleep quality in Sri Lankan children? A questionnaire
study. Pediatr Pulmonol 42: 579–583.
31. Valery PC, Masters IB, Chang AB (2004) Snoring and its association with
asthma in indigenous children living in the Torres Strait and Northern Peninsula
Area. J Paediatr Child Health 40: 461–465.
32. Teculescu DB, Caillier I, Perrin P, Rebstock E, Rauch A (1992) Snoring in
French preschool children. Pediatr Pulmonol 13: 239–244.
33. Redline S, Tishler PV, Schluchter M, Aylor J, Clark K, et al. (1999) Risk factors
for sleep-disordered breathing in children. Associations with obesity, race, and
respiratory problems. Am J Respir Crit Care Med 159: 1527–1532.
34. Marshall NS, Almqvist C, Grunstein RR, Marks GB, Childhood Asthma
Prevention Study (2007) Predictors for snoring in children with rhinitis at age 5.
Pediatr Pulmonol 42: 584–591.
35. Lu LR, Peat JK, Sullivan CE (2003) Snoring in preschool children: prevalence and
association with nocturnal cough and asthma. Chest 124: 587–593.
36. Kaditis AG, Kalampouka E, Hatzinikolaou S, Lianou L, Papaefthimiou M, et al.
(2010) Associations of tonsillar hypertrophy and snoring with history of wheezing
in childhood. Pediatr Pulmonol 45: 275–280.
37. Ersu R, Arman AR, Save D, Karadag B, Karakoc F, et al. (2004) Prevalence of
snoring and symptoms of sleep-disordered breathing in primary school children
in Istanbul. Chest 126: 19–24.
38. Corbo GM, Fuciarelli F, Foresi A, De Benedetto F (1989) Snoring in children:
association with respiratory symptoms and passive smoking. BMJ 299: 1491–1494.
39. Chng SY, Goh DY, Wang XS, Tan TN, Ong NB (2004) Snoring and atopic
disease: a strong association. Pediatr Pulmonol 38: 210–216.
40. Ko YA, Song PX, Clark NM (2014) Declines with age in childhood asthma
symptoms and health care use. An adjustment for evaluations. Ann Am Thorac
Soc 11: 54–62.
41. Weatherly RA, Mai EF, Ruzicka DL, Chervin RD (2003) Identification and
evaluation of obstructive sleep apnea prior to adenotonsillectomy in children: a
survey of practice patterns. Sleep Med 4: 297–307.
42. Friedman NR, Perkins JN, McNair B,Mitchell RB (2013) Current practice patterns
for sleep-disordered breathing in children. Laryngoscope 123: 1055–1058.
43. Gozal D, Capdevila OS, Kheirandish-Gozal L (2008) Metabolic alterations and
systemic inflammation in obstructive sleep apnea among nonobese and obese
prepubertal children. Am J Respir Crit Care Med 177: 1142–1149.
44. Gogate S, Katial R (2008) Pediatric biomarkers in asthma: exhaled nitric oxide,
sputum eosinophils and leukotriene E4. Curr Opin Allergy Clin Immunol 8:
154–157.
45. Prasad B, Nyenhuis SM, Weaver TE (2014) Obstructive sleep apnea and
asthma: associations and treatment implications. Sleep Med Rev 18: 165–171.
46. Ioachimescu OC, Teodorescu M (2013) Integrating the overlap of obstructive
lung disease and obstructive sleep apnoea: OLDOSA syndrome. Respirology 18:
421–431.
47. Dixon AE (2009) Rhinosinusitis and asthma: the missing link. Curr Opin Pulm
Med 15: 19–24.
48. Van Dole KB, Swern AS, Newcomb K, Nelsen L (2009) Seasonal patterns in
health care use and pharmaceutical claims for asthma prescriptions for preschool-
and school-aged children. Ann Allergy Asthma Immunol 102: 198–204.
49. Sears MR (2008) Epidemiology of asthma exacerbations. J Allergy Clin
Immunol 122: 662–668.
50. Gozal D, Shata A, Nakayama M, Spruyt K (2011) Seasonal variability of sleep-
disordered breathing in children. Pediatr Pulmonol 46: 581–586.
51. Saito H, Asakura K, Hata M, Kataura A, Morimoto K (1996) Does
adenotonsillectomy affect the course of bronchial asthma and nasal allergy?
Acta Otolaryngol Suppl 523: 212–215.
52. Busino RS, Quraishi HA, Aguila HA, Montalvo E, Connelly P (2010) The impact of
adenotonsillectomy on asthma in children. Laryngoscope 120 (Suppl 4): S221.
53. Crocker D, Brown C, Moolenaar R, Moorman J, Bailey C, et al. (2009) Racial
and ethnic disparities in asthma medication usage and health-care utilization:
data from the National Asthma Survey. Chest 136: 1063–1071.
54. Blixen CE, Havstad S, Tilley BC, Zoratti E (1999) A comparison of asthma-
related healthcare use between African-Americans and Caucasians belonging to
a health maintenance organization (HMO). J Asthma 36: 195–204.
55. Gilliland FD, Berhane K, Islam T, McConnell R, Gauderman WJ, et al. (2003)
Obesity and the risk of newly diagnosed asthma in school-age children.
Am J Epidemiol 158: 406–415.
56. Ewing R, Brownson RC, Berrigan D (2006) Relationship between urban sprawl
and weight of United States youth. Am J Prev Med 31: 464–474.
57. Statham MM, Myer CM 3rd (2010) Complications of adenotonsillectomy. Curr
Opin Otolaryngol Head Neck Surg 18: 539–543.
58. Goldman JL, Baugh RF, Davies L, Skinner ML, Stachler RJ, et al. (2013)
Mortality and major morbidity after tonsillectomy: etiologic factors and
strategies for prevention. Laryngoscope 123: 2544–2553.
Adenotonsillectomy and Asthma in Children
PLOS Medicine | www.plosmedicine.org 12 November 2014 | Volume 11 | Issue 11 | e1001753
Editors’ Summary
Background. The global burden of asthma has been rising
steadily over the past few decades. Nowadays, about 200–
300 million adults and children worldwide are affected by
asthma, a chronic condition caused by inflammation of the
airways (the tubes that carry air in and out of the lungs).
Although asthma can develop at any age, it is often
diagnosed in childhood—asthma is one of the commonest
chronic diseases in children. In the US, for example, asthma
affects around 7.1 million children under the age of 18 years
and is the third leading cause of hospitalization of children
under the age of 15 years. In people with asthma, the
airways can react very strongly to allergens such as animal
fur or to irritants such as cigarette smoke. Exercise, cold air,
and infections can trigger asthma attacks, which can be fatal.
The symptoms of asthma include wheezing, coughing, chest
tightness, and shortness of breath. Asthma cannot be cured,
but drugs can relieve its symptoms and prevent acute
asthma attacks.
WhyWas This Study Done? Recent studies have found an
association between severe childhood asthma and obstruc-
tive sleep apnea (OSA). In OSA, airway inflammation
promotes hypertrophy (excess growth) of the adenoids
and the tonsils, immune system tissues in the upper airway.
During sleep, the presence of hypertrophic adenotonsillar
tissues predisposes the walls of the throat to collapse, which
results in apnea—a brief interruption in breathing. People
with OSA often snore loudly and frequently wake from deep
sleep as they struggle to breathe. Childhood OSA, which
affects 2%–3% of children, can be effectively treated by
removal of the adenoids and tonsils (adenotonsillectomy).
Given the association between childhood OSA and severe
asthma and given the involvement of airway inflammation in
both conditions, might adenotonsillectomy also improve
childhood asthma? Here, the researchers analyze data from
the MarketScan database, a large database of US patients
with private health insurance, to investigate whether
adenotonsillectomy is associated with improvements in
asthma outcomes and with reductions in the use of asthma
therapies in children.
What Did the Researchers Do and Find? The researchers
used the database to identify 13,506 children with asthma
who had undergone adenotonsillectomy and to obtain
information about asthma outcomes among these children
for the year before and the year after the operation. Because
asthma severity tends to decrease with age, the researchers
also used the database to identify 27,012 age-, sex-, and
geographically matched children with asthma who did not
have the operation so that they could examine asthma
outcomes over an equivalent two-year period in the absence
of complications related to adenotonsillar hypertrophy.
Comparing the year after adenotonsillectomy with the year
before the operation, adenotonsillectomy was associated
with a 30% reduction in acute asthma exacerbations, a 37.9%
reduction in acute status asthmaticus (an asthma attack that
is unresponsive to the drugs usually used to treat attacks), a
25.6% reduction in asthma-related emergency room visits,
and a 35.8% reduction in asthma-related hospitalizations. By
contrast, among the control children, there was only a 2%
reduction in acute asthma exacerbations and only a 7%
reduction in acute status asthmaticus over an equivalent
two-year period. Adenotonsillectomy was also associated
with significant reductions (changes unlikely to have
occurred by chance) in prescription refills for most types of
drugs used to treat asthma, whereas there were no
significant reductions in prescription refills among children
with asthma who had not undergone adenotonsillectomy.
The study was limited by the lack of measures of race and
obesity, which are both associated with severity of asthma.
What Do These Findings Mean? These findings show
that in a large sample of privately insured children in the US,
adenotonsillectomy was associated with significant im-
provements in several asthma outcomes. These results do
not show, however, that adenotonsillectomy caused a
reduction in the severity of childhood asthma. It could be
that the children who underwent adenotonsillectomy (but
not those who did not have the operation) shared another
unknown factor that led to improvements in their asthma
over time. To prove a causal link, it will be necessary to
undertake a randomized controlled trial in which the
outcomes of groups of children with asthma who are
chosen at random to undergo or not undergo adenoton-
sillectomy are compared. However, with the proviso that
there are some risks associated with adenotonsillectomy,
these findings suggest that the detection and treatment of
adenotonsillar hypertrophy may help to improve asthma
control in children.
Additional Information. Please access these websites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1001753.
N The US Centers for Disease Control and Prevention
provides information on asthma, including videos,
games, and links to other resources for children with
asthma
N The American Lung Association provides detailed informa-
tion about asthma and a fact sheet on asthma in children;
it also has information about obstructive sleep apnea
N The National Sleep Foundation provides information on
snoring and obstructive sleep apnea in children
N The UK National Health Service Choices website provides
information (including some personal stories) about
asthma, about asthma in children, and about obstructive
sleep apnea
N The ‘‘Global Asthma Report 2014’’ will be available in
October 2014
N MedlinePlus provides links to further information on
asthma, on asthma in children, on sleep apnea, and on
tonsils and adenoids (in English and Spanish)
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